Complicated Horton's syndrome: Therapeutic modalities;La maladie de Horton compliquée: Modalités thérapeutiques

Presse Medicale

Volumn 33, Issue 1, 2004, Pages 51-59

  Agard, Christian ^a   Barrier, Jacques Henri ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

CORTICOSTEROID THERAPY; DRUG CHOICE; DRUG HYPERSENSITIVITY; HEMOLYSIS; HUMAN; INFECTION; LIVER TOXICITY; LUNG FIBROSIS; METHEMOGLOBINEMIA; OSTEOPOROSIS; REVIEW; TEMPORAL ARTERITIS; TREATMENT INDICATION;

EID: 0842286635     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(04)98475-8     Document Type: Review

References (73)

1. Salvarini C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 2002; 347: 261-71.
2. Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997; 81: 195-219.
3. e édition. Paris: Flammarion Médecine-Sciences 2000: 659-684.
4. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids. Results in fifty-five cases in which lesion was proved at biopsy. JAMA 1957; 163: 821-7.
5. Evans JM, Bowles CA, Bjornsson J, Mullany CJ, GG H. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994; 10: 1539-47.
6. Lie IT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arth and Rheum 1995; 24: 422-31.
7. Liu G, Shupak R, Chiu BKY. Aortic dissection in giant-cell arteritis. Semin Arth Rheum 1995; 25: 160-71.
8. Murai T, Saito K, Kuroda N et al. Acute aortic dissection due to giant cell arteritis. Report of two autopsy cases. Acta Pathol Jpn 1989; 39: 821-6.
9. Nordborg E, Bengtsson BA. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. Br Med J 1989; 299: 549-50.
10. Evans JM, O'Fallon WM, GG. H. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995; 122: 502-7.
11. Barrier JH. Treatment of giant cell arteritis. Ann Med Interne 1994; 145: 533-7.
12. Liozon F. Le traitement de la maladie de Horton. Quelles modalités pour la corticothérapie? Ann Med Interne 1992; 143: 83-4.
13. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophtalmology 2003; 110: 1204-15.
14. Généreau T, Cabane J. Bénéfices des corticoïdes lors du traitement de la maladie de Horton et de la pseudo-polyarthrite rhizomélique: avantages et inconvénients. Une méta-analyse. Rev Med Interne 1992; 13: 387-91.
15. Barrier J, Tournemaine N, Maulaz D et al. Evolution, traitement et pronostic de la maladie de Horton. Ann Med Interne 1983; 134: 428-35.
16. Säve-Söderbergh J, Bo-Eric M, Anderson R, Bengtsson BA. Giant cell arteritis as a cause of death. JAMA 1986; 255: 493-6.
17. Agard C, Ponge T, Hamidou M, Barrier J. Role for vascular investigations in giant cell arteritis. Joint Bone Spine 2002; 69: 367-72.
18. Evans JM, Hunder GG. The implications of recognizing large-vessel involvement in elderly patients with giant cell arteritis. Current Opinion in Rheumatology 1997; 9: 37-40.
19. Schmidt WA, Kraft HE, Borkowski A, Gromnica-Ihle EJ. Color duplex ultrasonography in large-vessel giant cell arteritis. Scand J Rheumatol 1999; 28: 374-6.
20. Chevalet P, Barrier JH, Pottier P et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000; 27: 1484-91.
21. Healey LA, Wilske KR. Treatment of resistant giant cell arteritis. Arthritis Rheum 1983; 26: 930.
22. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 1041-8.
23. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-8.
24. Généreau T, Lortholary O, Pottier MA et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. Arthritis Rheum 1999; 42: 2674-81.
25. Airo P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002; 41: 347-9.
26. Cantini P, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001; 44: 2933-5.
27. Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003; 62: 1116.
28. De Vira S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, Bombardieri S. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 1992; 232: 373-5.
29. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-14.
30. Liozon F, Barrier J, Vidal E et al. La dapsone dans le traitement de la maladie de Horton. Efficacité et tolérance. Rev Med Interne 1990; 11: 364-70.
31. Wilke WS, Hoffman GS. Treatment of corticosteroids-resistant giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 59-71.
32. Hernandez-Garcia C, Soriano C, Morado C et al. Methotrexate tretment in the management of giant cell arteritis. Scand J Rheumatol 1994; 23: 295-8.
33. Van der Veen MJ, Dinant HJ, Van Booma-Frankfort C, Van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55: 218-23.
34. Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-18.
35. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/ polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136-8.
36. David-Chausse J, Dehais J, Leman A. Résultats d'une enquête régionale sur le traitement de la pseudo-polyarthrite rhizomélique et de l'artérite temporale. À propos de 242 observations traitées selon diverses modalités par les antipaludéens de synthèse, les corticoïdes et les anti-inflammatoires non stéroïdiens. Rev Rhum 1983; 50: 263-71.
37. Le Guennec P, Dromer C, Sixou L, Marc V, Coustals P, Fourni B. Traitement de la maladie de horton: intérêt des antipaludéens de synthèse. Rev Rhum 1994; 61: 485-90.
38. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457-66.
39. Kaiser M, Weyand CM, Björnsson J, JJ G. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41 (4): 623-33.
40. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-5CID chimeras. J Clin Invest 1997; 99: 2842-50.
41. Huston KA, Hunder GG, Lie JT, Kennedy RH, LR. E. Temporal arteritis. A 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978; 88: 162-7.
42. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V et al. Permanent visual loss and cerebrovascular accidents in giant (ell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41: 1497-504.
43. Liozon E, Herrmann F, Ly K et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001; 111: 211-17.
44. Cid MC, Font C, Orristrelli J et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 26-32.
45. Hunder GG. Giant cell (temporal) arteritis. Rheum Dis Clin North Am 1990; 16: 399-409.
46. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83: 806-12.
47. Perruquet JL, Davis DE, Harrington TM. Aortic arch arteritis in the ederly. An important manifestation of giant cell arteritis. Arch Intern Med 1986; 146: 289-91.
48. Ninet JP, Bachet P, Dumontet CM, Bureau Du Colombier P, Stewart MD, Pasquier JH. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med 1990; 88: 13-20.
49. Östberg G. On arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand 1973; 237 (A suppl): 1-59.
50. Liozon F, Weinbreck P, Vidal E et al. Sténoses des artères des membres supérieurs dans l'artérite temporale de Horton. À propos de 3 observations. Revue de la littérature. Ann Med Interne 1986; 137: 307-12.
51. Jouquan J, Mottier D, Cleuziou A et al. Accidents vasculaires cérébraux précoces au cours de maladies de Horton traitées. Responsabilité du traitement corticoïde? Ann Med Interne 1984; 135 (7): 526-29.
52. Paccalin M, Amoura Z, Roblot P, Godeau P, Becq-Giraudon B, JC P. Accidents vasculaires encéphaliques précoces après instauration d'une corticothérapie au cours de la maladie de Horton. Rev Med Interne 2000; 21: 550-4.
53. Ponge T, Barrier J, Mottier D et al. Les accidents vasculaires cérébraux au cours de la maladie de Horton. À propos de huit observations. Sem Hôp Paris 1984; 60: 2365-70.
54. Caselli RJ, Hunder GG, Whisnart JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988; 38: 3S2-9.
55. Graham E, Holland A, Avery A, Ross Russel RW. Prognosis in giant cell arteritis. Br Med J 1981; 282: 269-72.
56. Greene GM, Lain D, Sherwin RM, Wilson JE, Mc Manus BM. Giant cell arteritis of the legs. Clinical isolation of severe disease with gangrene and amputations. Am J Med 1986; 81: 727-33.
57. Le Tourneau T, Millaire A, Asseman P, de Groote P, Théry C, Ducloux G. Aortite de Horton. Ann Med Interne 1996; 147: 361-8.
58. Richardson MP, Lever AML, Fink AM, Dixon AK, Hazleman BL Survival after aortic dissection in giant cell arteritis. Ann Rheum dis 1996; 55: 332-3.
59. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283-6.
60. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6.
61. Chevalet P, Barrier JH, Glémarec J et al. Maladie de Horton du sujet âgé de plus de 75 ans: particularités évolutives, complications de la corticothérapie. Etude comparative sur une série de 164 patients. Vers une dose d'attaque réduite. Rev Med Interne 2001; 22: 624-30.
62. Cacoub P, Chemlal K, Khalifa P et al. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol 2001; 28: 2474-9.
63. American College of Rheumatology task force on osteopoross guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39: 1791-801.
64. Werth VP. Glucocorticoid-induced osteoporosis: prevention and treatment. Joint Bone Spine 1997; 64: 845-85.
65. American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-503.
66. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997: 382-7.
67. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33: 348-50.
68. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997; 61: 266-71.
69. Nordborg E, Schaufelberger C, Andersson R, Bosaeus I, Bengtsson BA. The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant-cell arteritis. J Intern Med 1997; 242: 367-71.
70. Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Joint Bone Spine 1999; 66: 214-19.
71. Chevalet P, Masseau-Imbert A, Durand-Fix MH et al. Giant cell arteritis after the age of 75. Ann Med Interne 2002; 153: 373-7.
72. Struys A, Snelder AA, Mulder H et al. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995; 99: 235-42.
73. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampicin-induced non responsiveness of giant-cell arteritis to prednisone treatment. Arch Intern Med 1994; 154: 1521-4.